SCHEMBL2882437

SCHEMBL2882437

COC(=O)C1CCc2ccncc2C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 6/20 0.40
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NAMPT P43490 1/20 0.36
FGFR1 P11362 1/20 0.35
SRC P12931 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR4 P22455 1/20 0.35
FGFR3 P22607 1/20 0.35
FDPS P14324 1/20 0.35
RIPK1 Q13546 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
ACHE P22303 1/20 0.34
ABL1 P00519 1/20 0.33
PPARD Q03181 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26120276 0.85 MAPT (0.37) CYP19A1KDM4EMEN1MAPTKMT2A
SCHEMBL578148 0.80 ACHE (0.50) CYP19A1KDM4EMAPTL3MBTL1ALDH1A1
SCHEMBL30023013 0.80 ACHE (0.50) CYP19A1KDM4EMAPTL3MBTL1ALDH1A1
SCHEMBL2883246 0.78 KMT2A (0.45) CYP19A1KDM4EKMT2ANAMPTALDH1A1
SCHEMBL924439 0.77 CYP19A1 (0.46) CYP19A1ALDH1A1PPARD
SCHEMBL19852558 0.77 KMT2A (0.47) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL23461083 0.76 ACHE (0.45) CYP19A1KDM4EMEN1MAPTKMT2A
SCHEMBL38662922 0.76 ACHE (0.45) CYP19A1KDM4EMEN1MAPTKMT2A
SCHEMBL14799640 0.75 CYP11B1 (0.33) KDM4EMAPT
SCHEMBL7118501 0.75 ACHE (0.47) KDM4EMEN1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1930145-B Cycloalkanopyridine derivative MSD CO LTD 2011-06-15 CN disclosed
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
CN-1930145-A Cycloalkanopyridine derivative BANYU PHARMA CO LTD (JP) 2007-03-14 CN disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 CYP19A1 1945/4885KDM4E 3605/4885MEN1 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.